
ACRS
Healthcare · Biotechnology · $621.8M market cap
$3.92-0.08 (-2.0%)Nov 13, 4:00 PM EST
Next report
Before the open
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +5.5% over 90 days · 30-day revisions 2 up, 2 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 25, 2027 · upcoming | Before the open | -0.16 | — | — |
| Nov 5, 2026 | Before the open | -0.16 | -0.12 | +25.0% |
| Aug 6, 2026 | Before the open | -0.16 | -0.15 | +6.3% |
| May 7, 2026 | Before the open | -0.16 | -0.15 | +6.3% |
| Feb 26, 2026 | Time not confirmed | -0.15 | -0.16 | -6.7% |
| Nov 6, 2025 | Before the open | -0.14 | -0.12 | +14.3% |
| Aug 7, 2025 | Before the open | -0.13 | -0.13 | 0.0% |
| May 8, 2025 | Before the open | -0.12 | -0.12 | 0.0% |
| Feb 25, 2025 | Before the open | -0.38 | -1.01 | -169.3% |
| Nov 6, 2024 | Before the open | -0.01 | -0.11 | -1000.0% |
| Aug 7, 2024 | Before the open | -0.20 | -0.15 | +25.0% |
| May 7, 2024 | After the close | -0.29 | -0.24 | +17.2% |
| Feb 27, 2024 | Before the open | -0.39 | -0.02 |
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with…
| +94.9% |
| Nov 6, 2023 | Before the open | -0.49 | -0.41 | +16.3% |
| Aug 7, 2023 | Before the open | -0.45 | -0.42 | +6.7% |
| May 8, 2023 | Before the open | -0.44 | -0.42 | +4.5% |
| Feb 23, 2023 | Before the open | -0.45 | -0.41 | +8.9% |
| Nov 8, 2022 | Before the open | -0.40 | -0.30 | +25.0% |
| Aug 3, 2022 | Before the open | -0.36 | -0.31 | +13.9% |
| May 10, 2022 | Before the open | -0.41 | -0.31 | +24.4% |
| Feb 24, 2022 | Before the open | -0.36 | -0.37 | -2.8% |
| Nov 2, 2021 | Before the open | -0.28 | -0.35 | -25.0% |
| Aug 5, 2021 | Before the open | -0.28 | -0.34 | -21.4% |
| May 7, 2021 | Before the open | -0.28 | -0.57 | -103.6% |
| Feb 25, 2021 | Before the open | -0.27 | -0.30 | -11.1% |
| Nov 4, 2020 | Before the open | -0.28 | -0.25 | +10.7% |
| Aug 7, 2020 | Before the open | -0.33 | -0.28 | +15.2% |
| May 7, 2020 | After the close | -0.32 | -0.37 | -15.6% |
| Feb 25, 2020 | After the close | -0.32 | -0.46 | -43.8% |
| Nov 7, 2019 | After the close | -0.69 | -0.56 | +18.8% |
| Aug 8, 2019 | After the close | -0.72 | -1.21 | -68.1% |
| May 8, 2019 | After the close | -0.76 | -0.91 | -19.7% |
| Mar 18, 2019 | Before the open | -0.99 | -0.99 | 0.0% |
| Nov 6, 2018 | After the close | -1.12 | -1.06 | +5.4% |
| Aug 3, 2018 | Before the open | -1.00 | -1.01 | -1.0% |
| May 8, 2018 | After the close | -1.00 | -0.98 | +2.0% |
| Mar 12, 2018 | Before the open | -0.86 | -0.80 | +7.0% |